Our Focus

Our Commitment

The lack of innovation across permanent birth control and front-end infertility over the past few decades has left women with limited and antiquated options. Our pipeline seeks to answer the call for improved standards of care as we bring to market in-office technologies that are safe, natural, and minimally invasive.

PERMANENT BIRTH CONTROL

Since surgical tubal ligation was first performed in the 1880s, it remains the only permanent birth control option for women. Although effective, surgery can be associated with scarring from incisions, increased safety risks resulting from use of anesthesia, complications from the surgery itself, and the need for recovery time.

When surgery is not a suitable option, many women use hormonal birth control, which can result in severe side effects and increased safety risks, particularly as a woman ages. See how we are pioneering a new way forward in permanent birth control for women.

Explore Our Pipeline

In the US

MORE THAN 13 MILLION no longer intend to have children MORE THAN 12 MILLION WOMEN use non-permanent birth control long-term 800,000 WOMEN choose tubal ligation every year 1,000,000 800,000 600,000 400,000 200,000 0 MORE THAN 100 YEARS of stagnant innovation for permanent birth control
MORE THAN 13 MILLION no longer intend to have children MORE THAN 12 MILLION WOMEN use non-permanent birth control long-term 800,000 WOMEN choose tubal ligation every year 1,000,000 800,000 600,000 400,000 200,000 0 MORE THAN 100 YEARS of stagnant innovation for permanent birth control
Although tubal ligation has been performed for over a century, women will benefit from an in-office approach that avoids the risks and discomforts associated with incisions, general anesthesia and surgery. FemBloc may expand much needed options for women seeking permanent contraception.
Paul D. Blumenthal, MD, MPH
Paul D. Blumenthal, MD, MPH
PROFESSOR OF OBSTETRICS AND GYNECOLOGY AT THE STANFORD UNIVERSITY MEDICAL CENTER

Dr. Blumenthal discusses the benefits of FemBloc and how it answers the growing need for permanent birth control options.

infertility

Infertility has become a significant global problem with limited advancements for first-line treatment options. See how we are innovating a first-and-only approach to deliver sperm directly to where conception occurs.

MORE THAN 10 MILLION WOMEN contend with infertility in the U.S. ~40-50% IS DUE TO MALE FACTOR Sperm counts worldwide have declined by >50%
MORE THAN 30 YEARS of stagnant innovation for front-end infertility
Explore Our Pipeline
For more than 20 years, current approaches to infertility treatment have been limited during the initial stage of therapeutic care, but with the advancement of FemaSeed, we believe a next generation intrauterine procedure may have the opportunity to truly change this traditional paradigm.
Dr. Glassner
Michael Glassner, MD
Founding Partner and Medical Director of Main Line Fertility & Reproductive Medicine